WINTON GROUP Ltd Reduces Stock Position in Arcus Biosciences, Inc. $RCUS

Posted by Geri Gentry on Jun 9th, 2026

WINTON GROUP Ltd cut its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 32.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 62,251 shares of the company’s stock after selling 29,978 shares during the quarter. WINTON GROUP Ltd’s holdings in Arcus Biosciences were worth $1,483,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Decheng Capital LLC increased its stake in shares of Arcus Biosciences by 242.3% in the 3rd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock worth $7,447,000 after acquiring an additional 387,609 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Arcus Biosciences in the 3rd quarter worth $5,147,000. Vanguard Group Inc. increased its stake in shares of Arcus Biosciences by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 6,629,453 shares of the company’s stock worth $90,161,000 after acquiring an additional 73,210 shares during the last quarter. Aberdeen Group plc acquired a new stake in shares of Arcus Biosciences in the 3rd quarter worth $4,418,000. Finally, Fisher Asset Management LLC increased its stake in shares of Arcus Biosciences by 727.1% in the 3rd quarter. Fisher Asset Management LLC now owns 729,153 shares of the company’s stock worth $9,916,000 after acquiring an additional 640,990 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 7,763 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $25.63, for a total transaction of $198,965.69. Following the completion of the transaction, the chief financial officer directly owned 84,161 shares in the company, valued at $2,157,046.43. This trade represents a 8.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,562 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $25.77, for a total value of $66,022.74. Following the transaction, the chief accounting officer owned 39,581 shares of the company’s stock, valued at $1,020,002.37. This trade represents a 6.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Monday, April 20th. Wall Street Zen downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Leerink Partners set a $47.00 target price on Arcus Biosciences in a research note on Monday, April 20th. Morgan Stanley raised their target price on Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Monday, May 11th. Finally, Citigroup raised their target price on Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.10.

Check Out Our Latest Stock Analysis on RCUS

Arcus Biosciences Stock Performance

NYSE RCUS opened at $23.26 on Tuesday. The stock has a market cap of $2.92 billion, a PE ratio of -7.31 and a beta of 0.85. The company has a current ratio of 4.04, a quick ratio of 4.04 and a debt-to-equity ratio of 0.19. Arcus Biosciences, Inc. has a twelve month low of $7.91 and a twelve month high of $28.72. The stock has a fifty day simple moving average of $23.88 and a 200-day simple moving average of $22.87.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. During the same quarter last year, the business earned ($1.14) earnings per share. The business’s revenue was down 39.3% compared to the same quarter last year. Equities analysts anticipate that Arcus Biosciences, Inc. will post -3.61 earnings per share for the current year.

Arcus Biosciences Profile

(Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.